Inhibrx Q2 Loss Widens to $36.7M; Cash at $133.3M Before $100M July Draw

summarizeSummary

Inhibrx's Q2 loss widened to $36.7M on higher interest costs, with $133.3M cash at quarter-end before a $100M July draw. FDA Form 483 observations during ozekibart BLA review add regulatory risk.

check_boxKey Events · Earnings and Guidance · INBX

• Q2 Net Loss Widens

  Net loss increased to $36.7 million from $28.7 million in Q2 2025, driven by higher interest expense ($5.7M vs $3.1M) and pre-commercialization costs.

• Cash Position and July Draw

  Cash and equivalents were $133.3 million at June 30, 2026. On July 15, the company drew $100 million under a new $325 million Oxford facility amendment, bringing total facility to $500 million.

• FDA Form 483 Observations

  New risk factor discloses FDA issued Form 483 observations to the company and some ChonDRAgon clinical investigators during BLA review for ozekibart, which could delay approval or lead to a complete response letter.

• Debt Expansion and Warrants

  July 2026 amendment provides up to $325 million additional funding; $100 million drawn at execution with warrants for 21,457 shares at $93.21 exercise price.

auto_awesomeAnalysis · INBX · Life Sciences

Inhibrx Biosciences reported a Q2 net loss of $36.7 million, up from $28.7 million a year earlier, driven by higher interest expense on its expanded Oxford debt facility and increased pre-commercialization spending. Cash and equivalents stood at $133.3 million as of June 30, 2026, but the company subsequently drew an additional $100 million under a July 15 amendment that expanded the facility to $500 million. The 10-Q also discloses that FDA issued Form 483 observations during BLA review for ozekibart, a new risk factor that could delay approval. The company expects cash to fund operations for at least 12 months.